Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $273

Benzinga Newsdesk www.benzinga.com Positive 86.4%

Neg 0% Neu 0% Pos 86.4%

Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $265 to $273.